Zheng, Zhiyu;
Williams, Gareth R;
Guo, Honghua;
Zheng, Yilu;
Xiu, Mengting;
Zhang, Yanyan;
Zhang, Huan;
... Zhu, Li-Min; + view all
(2025)
A Bi2O3-TiO2 Heterojunction for Triple-Modality Cancer Theranostics.
International Journal of Nanomedicine
, 20
pp. 5593-5610.
10.2147/IJN.S511891.
Preview |
Text
IJN-511891-a-bi2o3-tio2.pdf - Published Version Download (12MB) | Preview |
Abstract
PURPOSE: Owing to the limitations of single-mode cancer treatments, combination therapies have attracted much attention. However, constructing a platform for combination therapies in a simple and effective way and improving the overall treatment effect remains a challenge. Our aim was to combine sonodynamic therapy, radiotherapy and chemotherapy together and improve therapeutic outcomes within one nanoplatform. METHODS: In this work, we sought to exploit the properties of nanoscale heterojunctions to this end. A multifunctional Bi2O3-TiO2@polydopamine-doxorubicin (BTPD) nanoparticle platform was constructed as an anti-cancer theranostic. Under ultrasound irradiation, the Bi2O3-TiO2 core can generate singlet oxygen to damage tumor cells. Meanwhile, the high-Z Bi2O3 can attenuate the energy of X-rays and scatter secondary electrons to enhance radiation damage in the tumor. A thin coating of polydopamine (PDA) increases the biocompatibility but also gives the particles the ability for photoacoustic imaging. Doxorubicin, a DNA repair inhibitor which can hinder tumor recovery from radiation damage, was loaded onto the PDA. RESULTS: A comprehensive series of in vitro and in vivo assays demonstrated that the nanoparticles were effectively taken up into cancer cells, where they could induce ROS production and cause cell death. In vivo, this led to a marked reduction in tumor volume in a murine 4T1 cancer model. CONCLUSION: The formulations developed here have significant potential for future investigation and exploration in the treatment of cancer.
| Type: | Article |
|---|---|
| Title: | A Bi2O3-TiO2 Heterojunction for Triple-Modality Cancer Theranostics |
| Location: | New Zealand |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2147/IJN.S511891 |
| Publisher version: | https://doi.org/10.2147/ijn.s511891 |
| Language: | English |
| Additional information: | © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. |
| Keywords: | DNA repair inhibition, combination therapy, radiosensitization, sonodynamic therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10208553 |
Archive Staff Only
 |
View Item |
